7 results match your criteria: "Dartmouth Geisel School of Medicine and Dartmouth Hitchcock Medical Center[Affiliation]"
Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations.
Ann Allergy Asthma Immunol
March 2024
Departments of Medicine and Health Research Methods, Evidence & Impact, McMaster University, Hamilton, Canada; Evidence in Allergy Group, McMaster University and The Research Institute of St. Joe's Hamilton, Hamilton, Canada.
Article Synopsis
- The American Academy of Allergy, Asthma, and Immunology is updating its guidelines for managing atopic dermatitis (AD) due to advancements in treatment and evidence methods since the last update in 2012.
- A multidisciplinary panel, including AD specialists and patient representatives, created evidence-based guidelines emphasizing equity, diversity, and minimizing conflicts of interest while reviewing systematic evidence.
- The panel produced 25 recommendations to help manage AD and included practical implementation resources for patients, covering various treatment options like topical corticosteroids, calcineurin inhibitors, and more.
WAO consensus on DEfinition of Food Allergy SEverity (DEFASE).
World Allergy Organ J
March 2023
Translational Research in Paediatric Specialities Area, Division of Allergy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Article Synopsis
- There is currently no consensus on how to define and categorize the severity of food allergies, despite the existence of various scoring systems for anaphylactic reactions.
- The aim of this study was to develop a global scoring system, called DEFASE, that comprehensively assesses food allergy severity using input from international experts.
- The results showed strong agreement among experts on key components of the DEFASE score through a structured survey, marking it as the first comprehensive grading that considers the overall disease spectrum, not just individual reactions.
The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis.
J Allergy Clin Immunol
February 2023
Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, Ill.
These evidence-based guidelines support patients, clinicians, and other stakeholders in decisions about the use of intranasal corticosteroids (INCS), biologics, and aspirin therapy after desensitization (ATAD) for the management of chronic rhinosinusitis with nasal polyposis (CRSwNP). It is important to note that the current evidence on surgery for CRSwNP was not assessed for this guideline nor were management options other than INCS, biologics, and ATAD. The Allergy-Immunology Joint Task Force on Practice Parameters formed a multidisciplinary guideline panel balanced to include the views of multiple stakeholders and to minimize potential biases.
View Article and Find Full Text PDFMultifunctional Plant Virus Nanoparticles for Targeting Breast Cancer Tumors.
Vaccines (Basel)
August 2022
Virology Laboratory, Department of Cell & Systems Biology, University of Toronto, Toronto, ON M5S 3B2, Canada.
Breast cancer treatment using plant-virus-based nanoparticles (PVNPs) has achieved considerable success in preclinical studies. PVNP-based breast cancer therapies include non-targeted and targeted nanoplatforms for delivery of anticancer therapeutic chemo and immune agents and cancer vaccines for activation of local and systemic antitumor immunity. Interestingly, PVNP platforms combined with other tumor immunotherapeutic options and other modalities of oncotherapy can improve tumor efficacy treatment.
View Article and Find Full Text PDFBiologics for chronic rhinosinusitis with nasal polyposis: What should we do now without direct comparison trials?
Ann Allergy Asthma Immunol
August 2022
Dartmouth Geisel School of Medicine and Dartmouth Hitchcock Medical Center, Section of Allergy, Lebanon, New Hampshire.
Emerging Potential of Plant Virus Nanoparticles (PVNPs) in Anticancer Immunotherapies.
J Cancer Immunol (Wilmington)
January 2022
Department of Microbiology and Immunology, Dartmouth Geisel School of Medicine, Hanover, NH, United States.
Cancer immunotherapies using plant virus nanoparticles (PVNPs) have achieved considerable success in preclinical studies. PVNP based nanoplatforms can be endogenous immune adjuvants and act as nanocarriers that stabilize and deliver cancer antigens and exogenous immune adjuvants. Although they do not infect mammalian cells, PVNPs are viruses and they are variably recognized by pathogen pattern recognition receptors (PRR), activate innate immune cells including antigen-presenting cells (APCs), and increase the expression of costimulatory molecules.
View Article and Find Full Text PDFEmerging Subspecialties in Neurology: Neuroethics: An Emerging Career Path in Neurology.
Neurology
March 2022
From the Department of Neurology (M.J.Y.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Neurology (J.L.B.), Dartmouth Geisel School of Medicine and Dartmouth-Hitchcock Medical Center, Lebanon, NH.
Essential to responsible practice and progress in neurology and neuroscience research is robust engagement with associated ethical dimensions and challenges. By virtue of the privileged relationship between personhood and the brain, and the importance of properties of the nervous system to what for most makes life worth living, conditions that affect neurologic function introduce a growing host of novel ethical and philosophical issues. Rather than serving a reactionary role, it is important for neurologists to anticipate such issues and develop familiarity with ethical analysis to inform quality medical practice and to safeguard neuroscience research.
View Article and Find Full Text PDF